The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep (belantamab mafodotin.
Blenrep, an antibody-drug conjugate (ADC), was withdrawn from global markets in 2022 following disappointing results from a confirmatory trial, but after positive readouts from two pivotal Phase III trials, GSK has been working to bring the BCMA-targeted ADC back as a treatment for relapsed or refractory multiple myeloma.
The news that the FDA would be convening an AdCom on July 17 to discuss Blenrep was revealed in a federal register notice.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze